- Anodyne Nanotech, Inc., a Boston-based biotechnology company developing differentiated, transdermal forms of high-value drugs, closed a $4.2m seed funding
- Backers included Velocity Partners, Relativity Healthcare Fund and Big Pi Ventures
- The company also intends to use the funds to continue to develop its Hero Patch™ platform
- Anodyne Nanotech also provides a Hero Patch™ platform, which uses microneedle technology to deliver clinically meaningful doses of macromolecules and small molecules
- By incorporating solvent-free bulk drug substance directly into microscopic porosities, Anodyne can load high amounts of the drug onto each microneedle
- The company plans to conduct clinical trials to characterize the bioequivalence, safety and tolerability of several Hero Patch products
